image
Healthcare - Medical - Diagnostics & Research - NASDAQ - IE
$ 189.64
-5.19 %
$ 15.7 B
Market Cap
21.12
P/E
1. INTRINSIC VALUE

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services.[ Read More ]

The intrinsic value of one ICLR stock under the base case scenario is HIDDEN Compared to the current market price of 190 USD, ICON Public Limited Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ICLR

image
FINANCIALS
8.12 B REVENUE
4.89%
956 M OPERATING INCOME
20.23%
612 M NET INCOME
21.18%
1.16 B OPERATING CASH FLOW
106.11%
-227 M INVESTING CASH FLOW
-55.38%
-844 M FINANCING CASH FLOW
2.33%
2.03 B REVENUE
-4.25%
285 M OPERATING INCOME
1.05%
197 M NET INCOME
34.18%
403 M OPERATING CASH FLOW
86.07%
-124 M INVESTING CASH FLOW
-266.73%
-104 M FINANCING CASH FLOW
-47.20%
Balance Sheet Decomposition ICON Public Limited Company
image
Current Assets 3.41 B
Cash & Short-Term Investments 380 M
Receivables 2.9 B
Other Current Assets 132 M
Non-Current Assets 13.6 B
Long-Term Investments 46.8 M
PP&E 502 M
Other Non-Current Assets 13 B
Current Liabilities 2.83 B
Accounts Payable 132 M
Short-Term Debt 147 M
Other Current Liabilities 2.55 B
Non-Current Liabilities 4.92 B
Long-Term Debt 3.79 B
Other Non-Current Liabilities 1.13 B
EFFICIENCY
Earnings Waterfall ICON Public Limited Company
image
Revenue 8.12 B
Cost Of Revenue 6.31 B
Gross Profit 1.81 B
Operating Expenses 756 M
Operating Income 956 M
Other Expenses 344 M
Net Income 612 M
RATIOS
22.34% GROSS MARGIN
22.34%
11.78% OPERATING MARGIN
11.78%
7.54% NET MARGIN
7.54%
6.63% ROE
6.63%
3.60% ROA
3.60%
7.21% ROIC
7.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ICON Public Limited Company
image
Net Income 612 M
Depreciation & Amortization 627 M
Capital Expenditures -141 M
Stock-Based Compensation 55.7 M
Change in Working Capital -115 M
Others 29.5 M
Free Cash Flow 1.02 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ICON Public Limited Company
image
Wall Street analysts predict an average 1-year price target for ICLR of $362 , with forecasts ranging from a low of $295 to a high of $390 .
ICLR Lowest Price Target Wall Street Target
295 USD 55.56%
ICLR Average Price Target Wall Street Target
362 USD 90.68%
ICLR Highest Price Target Wall Street Target
390 USD 105.65%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ICON Public Limited Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
ICON Public Limited Company Being Investigated on Behalf of ICON Public Limited Company Investors. Contact Levi & Korsinsky For Details. NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024. accesswire.com - 3 days ago
Shareholders that Lost Money on ICON Public Limited Company (ICLR) Should Contact Levi & Korsinsky About Securities Fraud Investigation - ICLR NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024. accesswire.com - 4 days ago
Shareholder Rights Advocates at Levi & Korsinsky Investigate ICON Public Limited Company (ICLR) Regarding Possible Securities Fraud Violations NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ICON Public Limited Company ("ICON Public Limited Company") (NASDAQ:ICLR) concerning possible violations of federal securities laws. On October 23, 2024, ICON disclosed its financial results for the third quarter ending September 30, 2024. accesswire.com - 5 days ago
ICON Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether ICON Public Limited Company (NASDAQ: ICLR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material information adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. globenewswire.com - 5 days ago
eXp Realty Unveils Game-Changing ICON and Revenue Share Capping Incentive Programs at eXpcon Miami New initiatives designed to supercharge agent growth and unlock unprecedented earning potential New initiatives designed to supercharge agent growth and unlock unprecedented earning potential globenewswire.com - 2 weeks ago
ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery. zacks.com - 2 weeks ago
ICON Public Limited Company (ICLR) Q3 2024 Earnings Call Transcript ICON Public Limited Company (NASDAQ:ICLR ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Kate Haven - Vice President of Investor Relations Steve Cutler - Chief Executive Officer Brendan Brennan - Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Michael Cherny - Leerink Partners Luke Sergott - Barclays Justin Bowers - Deutsche Bank Ann Hynes - Mizuho Patrick Donnelly - Citi David Windley - Jefferies Max Smock - William Blair Michael Ryskin - Bank of America Dan Leonard - UBS Jailendra Singh - Truist Securities Eric Coldwell - Baird Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Casey Woodring - JPMorgan Charles Rhyee - TD Cowen Operator Good day, and thank you for standing by. Welcome to the ICON PLC Q3 Earnings Conference Call and Webcast. seekingalpha.com - 3 weeks ago
Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates Icon PLC (ICLR) came out with quarterly earnings of $3.35 per share, missing the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.30 per share a year ago. zacks.com - 3 weeks ago
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy? Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Icon PLC (ICLR) Trading 3.72% Higher on Oct 2 Shares of Icon PLC (ICLR, Financial) surged 3.72% in mid-day trading on Oct 2. The stock reached an intraday high of $295.09, up from its previous close of $284.51. gurufocus.com - 1 month ago
ICON plc Schedules Third Quarter 2024 Earnings Conference Call DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Third Quarter 2024 Earnings Conference Call. businesswire.com - 1 month ago
Here's Why Icon PLC (ICLR) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com - 2 months ago
8. Profile Summary

ICON Public Limited Company ICLR

image
COUNTRY IE
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 15.7 B
Dividend Yield 0.00%
Description ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Contact South County Business Park, Dublin, 18 https://www.iconplc.com
IPO Date May 15, 1998
Employees 42250
Officers Dr. Gary Curtis Senior Vice President of Global Clinical Pharmacology Dr. Peter Schueler Senior Vice President of Drug Development Services - CNS Dr. Steven A. Cutler MBA, Ph.D. Chief Executive Officer & Director Dr. John Climax Ph.D. Founder & Independent Non-Executive Director Mr. Thomas N. O'Leary Chief Information Officer Mr. Diarmaid Cunningham Chief Administrative Officer, General Counsel & Company Secretary Ms. Niamh Murphy Director of Corporate Communications Mr. David Green Vice President of Marketing Mr. Joe Cronin Chief Human Resources Officer Mr. Simon Holmes President of Corporate Investments & Partnerships